Biotechnology

Johns Hopkins Grant Project Looks at Small Cell Lung Cancer Treatment Resistances

 Researchers at the Johns Hopkins Kimmel Cancer Center received a $3.1 million grant to study the resistance of limited stage small cell lung cancer to a combination of chemotherapy and radiotherapy (chemoradiation). The National Institutes of Health awarded the grant to researchers from The Johns Hopkins University, co-led by Luigi Marchionni, M.D., Ph.D., assistant professor of oncology, Christine Hann, M.D., Ph.D., assistant professor of oncology, and Phuoc Tran, M.D., Ph.D., associate professor of
Infectious Diseases

Higher Doses of Rifampin Appear More Effective in Fighting TB Without Increasing Risk of Adverse Events

Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, killed more TB bacteria in sputum cultures, and the higher doses did so without increasing the adverse effects of treatment, according to a randomized controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine. In “Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial,” Gustavo E. Velásquez, MD, MPH, associate physician in
cancer Cancer Discovery

Novel Clinical Tool to Predict Patient Survival Rate and Treatment Outcomes for Early-Stage Lung Cancer

A team of researchers, led by Professor Lim Chwee Teck from the Department of Biomedical Engineering at the National University of Singapore (NUS) and NUS PhD candidate Ms Lim Su Bin, has leveraged open source data to develop a personalised risk assessment tool that can potentially predict patient survival rate and treatment outcomes of early-stage lung cancer patients. The tool uses a novel panel of 29 unique extracellular matrix (ECM)
cancer

Making Milestones Against Non-Small Cell Lung Cancer

 Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering the odds for people with non-small cell lung cancer (NSCLC), which makes up about 85 percent of lung cancer cases. “Progress has been enormous in the past 20 years,” said Roy Herbst,
cancer

Penn Study Identifies New Target to Fight Prostate, Lung Cancer

A newly identified molecular chain of events in a mouse model of prostate cancer highlights novel targets to treat it and other cancers. A team led by Marcelo Kazanietz, PhD, a professor of Systems Pharmacology and Translational Therapeutics, published in Cell Reports that the overexpression of a protein called PKCε with the loss of the tumor suppressor Pten causes the progression of prostate cancer. This deadly combination produces an uptick